Peply
← All Compounds

Inclusion of a compound does not constitute endorsement. Information sourced from published research and regulatory filings.

AOD-9604

Cat 2 → Pending Cat 1

Growth & Recovery · Research peptide (multiple suppliers)

Modified fragment of human growth hormone (amino acids 176-191) researched for lipolysis stimulation without affecting IGF-1 or insulin sensitivity. Not FDA-approved for any indication.

About

Mechanism
Modified fragment of human growth hormone (amino acids 176-191). Stimulates lipolysis and inhibits lipogenesis without affecting IGF-1 levels or insulin sensitivity.
Half-Life
Estimated 30-60 minutes
Route
subcutaneous
Frequency
Once daily

Clinical Dosing

250-500 mcgonce daily

Not FDA-approved for any indication. Currently FDA Category 2 (restricted). Pending return to Category 1 availability.

Dosing extrapolated from animal studies and community protocols. No large-scale human clinical trials.

Regulatory Status

FDA Category
Research peptide (FDA Category 2)
Reclassification
pending
Date Restricted
2023-09-29
Announced Return
2026-02-27

Status based on publicly available FDA communications. Verify at FDA.gov for authoritative guidance.

View full regulatory timeline →

Titration Protocols

Research Protocol

Source: Heffernan et al., Obesity Research, 2001

DoseDurationDraw (5 mg vial in 2mL)Notes
300 mcgMaintenance0.12 mL (12 units)Standard research dose, no titration

Available Vial Sizes

5 mg

5 mg vial

10 mg

10 mg vial

Citations

  1. [1]Effects of a Modified Fragment of Growth Hormone on Body Composition (mouse study; human SC dosing is community-derived). Obesity Research, 9(S4), A51. Link(Reviewed: 2026-02-27)